A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2017
At a glance
- Drugs AZD 0156 (Primary) ; Olaparib
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms AToM
- Sponsors AstraZeneca
- 28 Jun 2017 Planned End Date changed from 3 Mar 2020 to 2 Jun 2020.
- 28 Jun 2017 Planned primary completion date changed from 3 Mar 2020 to 2 Jun 2020.
- 20 Feb 2017 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.